Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Hib-MenCY-TT = GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine.
The study will be conducted in a single blind manner up to 30 days after administration of the booster dose; the extended safety follow-up after the booster dose will be conducted in an unblinded manner.
All subjects will receive Prevnar, M-M-R II and Varivax as study vaccines, preferencially co-administered with the booster dose of Hib-MenCY-TT/PedvaxHIB.
Note: This protocol posting deals with the objectives \& outcome measures for the booster phase of the study. The objectives \& outcome measures for the primary phase are presented in a separate protocol posting (NCT00345579)
Age
1–1
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subjects enrolled in the primary study (NCT00345579) are eligible for participating in the booster study
You may not be if
Subjects should not be administered M-M-R II and Varivax if any of these criteria apply:
History of measles, mumps, rubella or varicella.
Previous vaccination against measles, mumps, rubella or varicella.
Hypersensitivity to any component of the vaccines, including gelatin or neomycin.
Patients receiving immunosuppressive therapy.
Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.
Individuals with primary and acquired immunodeficiency states.
Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.